Pre-exposure prophylaxis (PrEP)

News
June 23, 2020

Under level 5 and 4 of South Africa’s COVID-19 lockdown regulations adolescent girls and young women (AGYW) aged 14 to 24 years could not meet face-to-face in specially created safe spaces with counsellors, as part of a combination HIV intervention programme.

News
May 22, 2020

UNAIDS warmly welcomes the announcement that the long-acting injectable cabotegravir is safe and effective in preventing HIV among gay men and other men who have sex with men and transgender women.

Resource
May 18, 2020

Introduction: 

Heterosexual men are not considered a key population in the HIV response and are mostly absent from pre-exposure prophylaxis (PrEP) studies to date. Yet, South African men face considerable HIV risk.

Resource
May 4, 2020

Status

Ongoing

Phase

Demo Project

Objective

News
April 14, 2020

The Department of Health aims to make a pill to prevent HIV infection available at all community health centres and primary healthcare clinics in South Africa by end September this year.

Resource
December 30, 2019
We examine acceptability of a long‐acting injectable PrEP among HIV‐uninfected women in Zimbabwe, South Africa and two United States phase 2 trial sites.
News
November 28, 2019

A second case of HIV transmission from someone interrupting their HIV therapy as part of a cure study has been published.

Blog
November 27, 2019
This installment wraps up the ACCESS PrEP blog series and talks about combination prevention, particularly the effects of oral PrEP use on condom use.
Blog
November 27, 2019
The third blog in this ACCESS PrEP blog series addresses health providers’ experiences with oral PrEP services. It explores their knowledge of oral PrEP and concerns about increased risky behaviour. Health providers also expressed concern about the challenges clients faced when accessing oral PrEP and the barriers to uptake, adherence and continuation.
Blog
November 27, 2019
This narrative, the second in the ACCESS PrEP blog series, focuses on PrEP-related side effects. It highlights the determination of some clients to continue using oral PrEP despite the side effects they were experiencing.